Paper36727646
Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV.
De La Torre-Tarazona E and 9 others. J Med Virol, 2023. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV. Papers, record 36727646. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36727646
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Anti-HIV Agents | Major topic |
| HIV Infections | Major topic |
| Humans | |
| SARS-CoV-2 | |
| Antibodies, Viral | |
| Integrase Inhibitors | |
| Spike Glycoprotein, Coronavirus | |
| Antibodies, Neutralizing |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42553076 | Humoral and cellular responses to SARS-CoV-2 variants after ancestral COVID-19 vaccines in people with HIV and lung transplant recipients. | Clin Transl Immunology | 2026 | https://conductscience.org/library/papers/42553076 | PubMed |
| 42382775 | Development and validation of a pseudotyped virus neutralization assay for quantification of anti-Lassa virus neutralizing antibodies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42382775 | PubMed |
| 41997994 | Antiretroviral therapy interferes with pseudovirus neutralization assays while Gag-specific T-cells influence mRNA vaccine outcomes in HIV patients. | Sci Rep | 2026 | https://conductscience.org/library/papers/41997994 | PubMed |
| 41573558 | Contrasting immune responses in COVID-19: insights from healthcare workers and infected patients on plasmablast, pDC, and NK cell dynamics. | Front Immunol | 2025 | https://conductscience.org/library/papers/41573558 | PubMed |
| 40764781 | Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors. | Sci Rep | 2025 | https://conductscience.org/library/papers/40764781 | PubMed |
| 38812512 | Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus. | Front Immunol | 2024 | https://conductscience.org/library/papers/38812512 | PubMed |
| 38448564 | Neutralizing immunity against coronaviruses in Tanzanian health care workers. | Sci Rep | 2024 | https://conductscience.org/library/papers/38448564 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36727646
GET https://conductscience.org/api/papers/v1/36727646/authors